Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.

Tyc, Katarzyna M; Kazi, Aslamuzzaman; Ranjan, Alok; Wang, Rui; Sebti, Said M

Tyc, Katarzyna M; Kazi, Aslamuzzaman; Ranjan, Alok; Wang, Rui; Sebti, Said M.

Afiliação

Tyc KM; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Kazi A; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Ranjan A; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Wang R; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Sebti SM; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

iScience ; 26(3): 106082, 2023 Mar 17.

Article em En | MEDLINE | ID: mdl-36852277

Palavras-chave

Cancer; Transcriptomics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google